ATE376673T1 - Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten - Google Patents
Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheitenInfo
- Publication number
- ATE376673T1 ATE376673T1 AT00952739T AT00952739T ATE376673T1 AT E376673 T1 ATE376673 T1 AT E376673T1 AT 00952739 T AT00952739 T AT 00952739T AT 00952739 T AT00952739 T AT 00952739T AT E376673 T1 ATE376673 T1 AT E376673T1
- Authority
- AT
- Austria
- Prior art keywords
- sibo
- diagnosis
- disclosed
- treatment
- fibromyalgia
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 208000002551 irritable bowel syndrome Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 abstract 6
- 230000007142 small intestinal bacterial overgrowth Effects 0.000 abstract 6
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 239000002325 prokinetic agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/12—Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
- H04L67/125—Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L69/00—Network arrangements, protocols or services independent of the application payload and not provided for in the other groups of this subclass
- H04L69/08—Protocols for interworking; Protocol conversion
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Computing Systems (AREA)
- Medical Informatics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/374,142 US6861053B1 (en) | 1999-08-11 | 1999-08-11 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE376673T1 true ATE376673T1 (de) | 2007-11-15 |
Family
ID=23475487
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07075358T ATE514946T1 (de) | 1999-08-11 | 2000-08-11 | Zusammensetzungen zur behandlung von darmirritationssyndromen |
AT00952739T ATE376673T1 (de) | 1999-08-11 | 2000-08-11 | Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07075358T ATE514946T1 (de) | 1999-08-11 | 2000-08-11 | Zusammensetzungen zur behandlung von darmirritationssyndromen |
Country Status (10)
Country | Link |
---|---|
US (9) | US6861053B1 (de) |
EP (5) | EP1200828B1 (de) |
AT (2) | ATE514946T1 (de) |
AU (1) | AU6538300A (de) |
CY (1) | CY1114368T1 (de) |
DE (1) | DE60036871T2 (de) |
DK (2) | DK2256498T3 (de) |
ES (3) | ES2295045T3 (de) |
PT (2) | PT2256498E (de) |
WO (1) | WO2001011077A2 (de) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5348986A (en) * | 1990-11-19 | 1994-09-20 | Loctite Corporation | Photocurable silicone composition, and method of making same |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
BR0108077A (pt) * | 2000-02-04 | 2002-10-22 | Children S Hospital Res Founda | Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero |
US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
DE60239316D1 (de) * | 2001-01-16 | 2011-04-14 | Univ Ramot | Hybridpeptide für die behandlung von bacteraemie und sepsis |
GB2371983A (en) * | 2001-02-12 | 2002-08-14 | Reckitt & Colmann Prod Ltd | Compositions to treat irritable bowel syndrome |
ATE499107T1 (de) * | 2002-05-20 | 2011-03-15 | Cedars Sinai Medical Center | Manipulation der rate des gastrointestinalen transits durch modulation der methankonzentration im darm |
US10066254B2 (en) * | 2002-05-20 | 2018-09-04 | Cedars-Sinai Medical Center | Diagnosis of constipation by analysis of methane concentration |
EP1511502A2 (de) * | 2002-06-13 | 2005-03-09 | Alimentary Health Limited | Probiotische therapien mit lactobazillus reuteri |
EP1384483A1 (de) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotische Mikroorganismen zur Behandlung von Colon Irritabile durch die Verbesserung der neuromuskulären Darmfunktion |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
EP1554580B1 (de) * | 2002-10-25 | 2008-05-14 | Techlab, Inc. | Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon |
US20040265279A1 (en) * | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
US7731976B2 (en) * | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
US20060177424A1 (en) * | 2003-08-29 | 2006-08-10 | Cobb Mark L | Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions |
US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
US7749509B2 (en) * | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
US7759105B2 (en) * | 2003-08-29 | 2010-07-20 | Cobb & Company, Llp | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
EP1720536B1 (de) * | 2004-02-06 | 2012-04-25 | PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST | Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom |
US7125963B2 (en) | 2004-03-03 | 2006-10-24 | En N Tech Inc | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions |
ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
WO2006021564A1 (en) * | 2004-08-26 | 2006-03-02 | Neurosearch A/S | Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors |
NZ554278A (en) * | 2004-09-03 | 2009-11-27 | Chr Hansen As | Fermented milk or vegetable proteins comprising receoptor ligand and uses thereof |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US20060078546A1 (en) * | 2004-10-07 | 2006-04-13 | Anders Zachrisson | Use of lactic acid bacteria to reduce sick time |
EP1698630B1 (de) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
US20090233888A1 (en) * | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
WO2007030375A2 (en) * | 2005-09-08 | 2007-03-15 | Children's Hospital Medical Center | Lysosomal acid lipase therapy for nafld and related diseases |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US8246946B2 (en) * | 2005-09-27 | 2012-08-21 | Cobb & Associates | Treatment of bipolar disorder utilizing anti-fungal compositions |
US7868139B2 (en) * | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
US8093299B2 (en) * | 2007-03-30 | 2012-01-10 | Amgen Inc. | Methods of treating bowel disorders |
EP2152318A4 (de) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | Anwendungen und zusammensetzungen zur behandlung von schuppenflechten und morbus crohn |
EP2026529A1 (de) * | 2007-07-12 | 2009-02-18 | Wayport, Inc. | Vorrichtungsspezifische Autorisierung an verteilten Standorten |
EP2987495A1 (de) | 2007-10-25 | 2016-02-24 | Yale University | Verwendung von phy906 als behandlung für entzündliche darmerkrankung und/oder reizdarm |
EP2231005A1 (de) * | 2007-12-19 | 2010-09-29 | Great Lakes Biosciences, LLC | Diagnose von hirnspezifischem chronischem schmerz und beurteilungsverfahren |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
FI20080321A0 (fi) * | 2008-04-25 | 2008-04-25 | Eino Elias Hakalehto | Menetelmä suoliston bakteeritasapainon ylläpitämiseksi |
WO2009137672A1 (en) * | 2008-05-07 | 2009-11-12 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (pl) * | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20110092493A1 (en) * | 2008-09-24 | 2011-04-21 | Clark Levi | Dose-controlled transdermal promethazine compositions and methods of use |
JP5567484B2 (ja) | 2008-09-26 | 2014-08-06 | あすか製薬株式会社 | 機能性消化管障害の予防及び/又は治療剤 |
CA2739436C (en) | 2008-10-02 | 2019-08-27 | Salix Pharmaceuticals, Ltd. | Use of rifaximin for treating hepatic encephalopathy |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
WO2010062959A1 (en) * | 2008-11-26 | 2010-06-03 | Aryx Therapeutics, Inc. | 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity |
ES2882518T3 (es) | 2009-01-06 | 2021-12-02 | Galenagen Llc | Composición que comprende proteasa, amilasa y lipasa |
ES2727746T3 (es) | 2009-01-06 | 2019-10-18 | Galenagen Llc | Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli |
WO2010093776A1 (en) * | 2009-02-11 | 2010-08-19 | Cedars-Sinai Medical Center | Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome |
ES2656850T3 (es) | 2009-02-11 | 2018-02-28 | Cedars-Sinai Medical Center | Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal |
US11693009B2 (en) | 2009-02-11 | 2023-07-04 | Cedars-Sinai Medical Center | Methods for detecting post-infectious irritable bowel syndrome |
US9056050B2 (en) * | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2010147957A2 (en) | 2009-06-15 | 2010-12-23 | Encore Health, Llc | Dithiol compounds, derivatives, and uses therefor |
US9848760B2 (en) * | 2009-06-29 | 2017-12-26 | Gearbox, Llc | Devices for continual monitoring and introduction of gastrointestinal microbes |
KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ibs)의 치료방법 |
EP2485744A4 (de) * | 2009-10-09 | 2014-01-22 | Prothera Inc | Zusammensetzungen und verfahren mit pediokokken zur reduzierung mindestens eines symptoms für autismusspektrumserkrankungen bei einem patienten mit diagnostizierter autismusspektrumserkrankung |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
ES2762442T3 (es) | 2009-10-26 | 2020-05-25 | Borody Thomas J | Novedosa terapia de combinación entérica |
PT3564357T (pt) | 2010-02-01 | 2022-06-14 | Rebiotix Inc | Bacterioterapia para colite por clostridium difficile |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
EP2575821B1 (de) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Gallensäurerückflusshemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen |
WO2012044984A1 (en) | 2010-09-30 | 2012-04-05 | The Board Of Trustees Of The University Of Arkansas | Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads |
US9114065B2 (en) | 2010-12-14 | 2015-08-25 | Kimberly-Clark Worldwide, Inc. | Method and system for monitoring nutritional uptake as a function of microflora intestinal gas levels |
US20120196887A1 (en) * | 2011-02-02 | 2012-08-02 | Darkoh Charles | Methods and compositions for improved rifamycin therapies |
US8623914B2 (en) * | 2011-02-10 | 2014-01-07 | Tsumura & Co. | Medical composition |
AU2012245287B2 (en) | 2011-04-21 | 2017-04-13 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
US20130017174A1 (en) * | 2011-07-12 | 2013-01-17 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for increasing health and reducing pathogenic bacteria in animals |
US20130017999A1 (en) * | 2011-07-14 | 2013-01-17 | Marc Fremont | Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
CA2853285C (en) | 2011-10-28 | 2020-05-05 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
US9055889B2 (en) | 2012-03-20 | 2015-06-16 | Commonwealth Laboratories, Inc. | Method and apparatus for breath testing |
AU2013240289B2 (en) | 2012-03-29 | 2018-01-25 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
WO2013161693A1 (ja) * | 2012-04-27 | 2013-10-31 | トライエックス・バイオメディカル株式会社 | 腸内細菌異常増殖による過敏性腸症候群の診断剤及び診断法 |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US20150216957A1 (en) | 2012-08-20 | 2015-08-06 | Boris Markosian | Placental vaccination therapy for cancer |
WO2014043320A1 (en) * | 2012-09-12 | 2014-03-20 | Salix Pharmaceuticals, Inc. | Methods of administering rifaximin without producing antibiotic resistance |
KR102203568B1 (ko) | 2012-09-17 | 2021-01-15 | 세다르스-신나이 메디칼 센터 | 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료 |
CA3101218A1 (en) | 2013-03-14 | 2014-09-25 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
US9289418B2 (en) | 2013-03-15 | 2016-03-22 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
JP2016516717A (ja) | 2013-03-15 | 2016-06-09 | シーダーズ−サイナイ メディカル センター | メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
WO2014197562A1 (en) | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
WO2015013591A1 (en) * | 2013-07-26 | 2015-01-29 | Cedars-Sinai Medical Center | Methods of treating irritable bowel syndrome |
JP5719985B2 (ja) * | 2013-08-01 | 2015-05-20 | 株式会社ポーラファルマ | ジフェニルメチルピペラジン誘導体 |
PT3054977T (pt) | 2013-10-09 | 2021-10-14 | Cedars Sinai Medical Center | Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal |
TWI505832B (zh) * | 2014-02-21 | 2015-11-01 | Genmont Biotech Inc | 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途 |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
PL3546464T3 (pl) | 2014-05-12 | 2020-11-02 | Alfasigma S.P.A. | Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME |
CN104076101A (zh) * | 2014-06-13 | 2014-10-01 | 门毅 | 利用hplc测定尼扎替丁及注射制剂中有关物质的方法 |
MX2017001971A (es) | 2014-08-13 | 2017-09-15 | Cedars Sinai Medical Center | Composiciones antimetanogenicas y sus usos. |
WO2016057772A1 (en) | 2014-10-09 | 2016-04-14 | Cedars-Sinai Medical Center | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
AU2015335907A1 (en) | 2014-10-21 | 2017-04-13 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
NO3193901T3 (de) | 2014-12-23 | 2018-09-01 | ||
DK3065748T3 (da) | 2014-12-23 | 2018-01-29 | 4D Pharma Res Ltd | En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation |
EP3277274B1 (de) | 2015-04-01 | 2024-06-12 | Cedars-Sinai Medical Center | Antimethanogene lovastatin-analoga oder -derivate und verwendungen davon |
US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
ES2889902T3 (es) | 2015-06-09 | 2022-01-14 | Rebiotix Inc | Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM) |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
TW202222339A (zh) | 2015-06-15 | 2022-06-16 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
SI3650033T1 (sl) | 2015-06-15 | 2022-05-31 | 4D Pharma Research Limited | Sestavki, ki obsegajo bakterijske seve |
EP3636272A1 (de) | 2015-06-15 | 2020-04-15 | 4D Pharma Research Limited | Zusammensetzungen mit bakterienstämmen |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MX2018006240A (es) | 2015-11-20 | 2018-08-01 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
SI3313423T1 (sl) | 2016-03-04 | 2019-07-31 | 4D Pharma Plc | Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP4104843A1 (de) | 2017-06-14 | 2022-12-21 | 4D Pharma Research Limited | Zusammensetzungen mit bakterienstämmen |
LT3638271T (lt) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterines padermes |
AU2019278927A1 (en) * | 2018-06-01 | 2020-12-24 | Biora Therapeutics, Inc. | Devices and systems for gastrointestinal microbiome detection and manipulation |
CN109055583B (zh) * | 2018-08-22 | 2022-02-01 | 江南大学 | 一种基于细胞水平筛选通过5-羟色氨酸相关途径实现抗抑郁功能的益生菌的方法 |
US11763920B2 (en) | 2019-07-31 | 2023-09-19 | Dig Labs Corporation | Mucus analysis for animal health assessments |
CA3148217A1 (en) | 2019-07-31 | 2021-02-04 | Dig Labs Corporation | Animal health assessment |
US20230077104A1 (en) * | 2020-02-19 | 2023-03-09 | The United States Government As Represented By The Department Of Veteran Affairs | L-sepiapterin and methods of use for treating diseases and disorders |
KR102166461B1 (ko) * | 2020-03-10 | 2020-10-15 | 주식회사 종근당바이오 | 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주 |
WO2022055993A1 (en) * | 2020-09-08 | 2022-03-17 | The Johns Hopkins University | Method of treatment of irritable bowel syndrome |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2023056419A1 (en) * | 2021-09-30 | 2023-04-06 | The General Hospital Corporation | Systems and methods for assessing medical conditions such as inflammation, autoimmunity, and autism spectrum disorder (asd) and treatments thereof |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US124566A (en) * | 1872-03-12 | Improvement in combined tools | ||
US37020A (en) * | 1862-11-25 | Improvement in quartz-crushers | ||
US152919A (en) * | 1874-07-14 | Improvement in clothes-driers | ||
US50308A (en) * | 1865-10-03 | James ware | ||
US185754A (en) * | 1876-12-26 | Improvement in rotary churns | ||
US68097A (en) * | 1867-08-27 | John mckenzie | ||
US18809A (en) * | 1857-12-08 | Improvement in life-preservers | ||
US215421A (en) * | 1879-05-13 | Improvement in steam-generators | ||
US3085936A (en) * | 1962-01-12 | 1963-04-16 | S B Penick & Company | Gastro-enteritis-diarrheal syndrome treatment |
GB1576376A (en) | 1977-03-30 | 1980-10-08 | Benzon As Alfred | Multiple-unit drug dose |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
IT1090759B (it) | 1977-11-29 | 1985-06-26 | Alfa Farmaceutici Spa | Procedimento per la preparazione di 3 iodio e 3 bromo rifamicina s |
IT1090772B (it) | 1977-12-20 | 1985-06-26 | Alfa Farmaceutici Spa | Derivati della rifamicina e procedimento per la loro preparazione |
US4183960A (en) | 1978-02-01 | 1980-01-15 | Exxon Research & Engineering Co. | Detoxification by means of the controlled, in vivo secretion triggered rupture of liquid membrane capsules |
JPS57500432A (de) | 1980-03-20 | 1982-03-11 | ||
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
US4386079A (en) * | 1981-11-23 | 1983-05-31 | The Upjohn Company | Method of treating depression |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4502974A (en) * | 1982-03-31 | 1985-03-05 | Chisso Corporation | High temperature liquid-crystalline ester compounds |
DK151608C (da) | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
CH657779A5 (de) | 1982-10-05 | 1986-09-30 | Sandoz Ag | Galenische zusammensetzungen enthaltend calcitonin. |
BE896241A (fr) * | 1983-03-22 | 1983-07-18 | Prosan Internat | Composition antidiarrheique a usage veterinaire et methode d'utilisation de cette composition |
US4530838A (en) | 1983-07-08 | 1985-07-23 | The Salk Institute For Biological Studies | Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals |
US4549986A (en) | 1983-12-23 | 1985-10-29 | The Salk Institute For Biological Studies | Human CGRP |
FR2557453B1 (fr) * | 1983-12-29 | 1988-02-19 | Virbac Ctre Rech Biolog | Nouvelle propriete pharmacocinetique des aminoglucosides |
US4701457A (en) | 1984-01-13 | 1987-10-20 | Rorer Pharmaceutical Corporation | Amidinoureas for treating irritable bowel syndrome |
US4611011A (en) | 1984-01-13 | 1986-09-09 | William H. Rorer, Inc. | Amidinoureas for treating irritable bowel syndrome |
US4562188A (en) | 1984-01-13 | 1985-12-31 | William H. Rorer, Inc. | Triazinones for treating irritable bowel syndrome |
US4573680A (en) * | 1984-03-14 | 1986-03-04 | Mcnally James C | Football training apparatus and methods of using same |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US4863744A (en) | 1984-09-17 | 1989-09-05 | Alza Corporation | Intestine drug delivery |
GB8507779D0 (en) | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
US4673680A (en) | 1985-09-18 | 1987-06-16 | Pendleton Robert G | α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility |
GB8525013D0 (en) * | 1985-10-10 | 1985-11-13 | Wyeth John & Brother Ltd | Antidiarrhoel agents |
US4990617A (en) | 1985-12-02 | 1991-02-05 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives |
WO1990007332A1 (en) | 1986-04-25 | 1990-07-12 | Hitoshi Shichi | Immunosuppressive agent |
US5869054A (en) | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5660828A (en) | 1988-03-02 | 1997-08-26 | Mayo Foundation For Medical Education & Research | Method of treating autoimmune and/or viral-induced diseases that are mediated by CD8 phenotype T cells |
US5236901A (en) | 1988-04-20 | 1993-08-17 | Research Corporation Technologies, Inc. | Treatment for irritable bowel syndrome |
US4970207A (en) | 1988-07-07 | 1990-11-13 | Fujisawa Pharmaceutical Company, Ltd. | Benzodiazepine derivatives |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
US5064858A (en) | 1988-08-17 | 1991-11-12 | Spectrum Pharmaceutical Corporation | Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease |
GB8823203D0 (en) | 1988-10-04 | 1988-11-09 | Pfizer Ltd | Therapeutic agents |
US5362756A (en) | 1989-02-20 | 1994-11-08 | Riviere Pierre J M | Use of fedotozine in the treatment of functional states of intestinal obstructions |
FR2651581B1 (fr) | 1989-09-06 | 1994-05-13 | Centre Nal Recherc Scientifique | Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques. |
US5177069A (en) | 1989-12-13 | 1993-01-05 | Kissei Pharmaceutical Co., Ltd. | Naphthysulfonylalkanoic acid compounds and pharmaceutical compositions thereof |
US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
US5120306A (en) | 1990-03-21 | 1992-06-09 | Gosselin Leon F | Direct delivery of anti-inflammatories to the proximal small bowel |
US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
US5723218A (en) * | 1990-04-16 | 1998-03-03 | Molecular Probes, Inc. | Dipyrrometheneboron difluoride labeled flourescent microparticles |
US5547961A (en) | 1990-05-25 | 1996-08-20 | Yamanouchi Pharmaceutical Co., Ltd. | Method of treatment of intestinal diseases |
US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
ATE147976T1 (de) | 1991-01-15 | 1997-02-15 | Hemosphere Inc | Protein nanomatrizen und verfahren zur herstellung |
US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
US5725804A (en) | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5616311A (en) | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
US5453428A (en) | 1991-02-14 | 1995-09-26 | The Mount Sinai School Of Medicine Of The City Of New York | Method and composition for the treatment of apathy-amotivation syndrome |
AU1578692A (en) | 1991-03-07 | 1992-10-06 | G.D. Searle & Co. | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents |
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US5145869A (en) | 1991-04-11 | 1992-09-08 | Kissei Pharmaceutical Co., Ltd. | Phenylsulfonylalkanoic acid compounds and pharmaceuticals thereof |
GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
US5426028A (en) | 1991-07-05 | 1995-06-20 | Rush-Presbyterian-St. Lukes Medical Center | Screening method for chronic immune dysfunction syndrome |
US5821259A (en) | 1991-11-12 | 1998-10-13 | Theoharides; Theoharis C. | H3 -receptor agonists as therapeutic agents |
IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
US5869262A (en) | 1992-01-27 | 1999-02-09 | Icos Corporation | Method for monitoring an inflammatory disease state by detecting circulating ICAM-R |
WO1993020717A2 (en) | 1992-04-13 | 1993-10-28 | Research Corporation Technologies, Inc. | Reducing gastrointestinal irritation in infant nutrition |
US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US5434174A (en) | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
WO1994003380A1 (en) | 1992-07-31 | 1994-02-17 | Marco Grillini | Refillable liquid mixtures aerosol dispensing container |
US5380522A (en) | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
JPH08502283A (ja) | 1992-10-16 | 1996-03-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht▲下4▼レセプターアンタゴニスト用の縮合環系n−アルキルピペリジニル−4−メチルカルボン酸エステル/アミド |
US5236407A (en) * | 1992-11-19 | 1993-08-17 | Lee Wang Industry Ltd. | Hydraulic exerciser |
US5354757A (en) | 1992-12-15 | 1994-10-11 | G. D. Searle & Co. | Azanoradamantanes |
PL177771B1 (pl) | 1992-12-18 | 2000-01-31 | Cell Med Inc | Linie komórek hybrydoma i preparaty przeciwciał |
ES2196023T3 (es) | 1993-01-06 | 2003-12-16 | Kinerton Ltd | Conjugados moleculares ionicos de poliesteres biodegradables y polipeptidos bioactivos. |
IT1264494B1 (it) * | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
AU685803B2 (en) | 1993-03-29 | 1998-01-29 | University Of Cincinnati, The | Analogs of peptide YY and uses thereof |
US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
JP3193205B2 (ja) | 1993-08-09 | 2001-07-30 | 日本臓器製薬株式会社 | 好酸球増多抑制剤 |
RU2133252C1 (ru) | 1993-08-09 | 1999-07-20 | Байомежер, Инк. | Производное пептида, способ лечения рака у пациента |
AU7707994A (en) | 1993-09-30 | 1995-04-18 | Tokyo Tanabe Company Limited | Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient |
ES2131297T3 (es) | 1993-11-29 | 1999-07-16 | Merrell Pharma Inc | Nuevos derivados de bencenosulfonilamina como inhibidores de la accion il-1. |
WO1995014670A1 (en) | 1993-11-29 | 1995-06-01 | Merrell Pharmaceuticals Inc. | Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action |
CA2138305A1 (en) | 1993-12-28 | 1995-06-29 | Naohito Ohashi | Tumor necrosis factor production inhibitors |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
CN1099619A (zh) * | 1994-03-08 | 1995-03-08 | 中国农业科学院畜牧研究所 | 防治猪腹泻的药物及其制备方法 |
US5443428A (en) * | 1994-04-29 | 1995-08-22 | April Engineering Corporation | Gearless mechanical transmission |
WO1995032963A1 (fr) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienylazole et compose de thienotriazolodiazepine |
US5550132A (en) | 1994-06-22 | 1996-08-27 | University Of North Carolina | Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines |
US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
US5627200A (en) | 1994-09-26 | 1997-05-06 | Pfizer Inc | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia |
US5834215A (en) | 1994-10-05 | 1998-11-10 | The Administrators Of The Tulane Educational Fund | Method for detecting antipolymer antibodies and diagnosing silicone related disease (SRD) fibromyalgia and chronic fatigue syndrome (CFS) |
US5696093A (en) | 1994-10-28 | 1997-12-09 | Crc For Biopharmaceutical Research Pty Limited | Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides |
US5703100A (en) | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
EP0716344A1 (de) * | 1994-12-05 | 1996-06-12 | Konica Corporation | Lichtempfindliche Zusammensetzung und lithographische Druckplatte |
US5599533A (en) | 1994-12-15 | 1997-02-04 | Estee Lauder, Inc. | Stable water-in-oil emulsion system |
US5589468A (en) | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5912227A (en) | 1995-01-27 | 1999-06-15 | North Carolina State University | Method of enhancing nutrient uptake |
US5691343A (en) * | 1995-03-30 | 1997-11-25 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine to treat inflammatory bowel disorders |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5716804A (en) * | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US5849708A (en) | 1995-06-06 | 1998-12-15 | Joslin Diabetes Center, Inc. | Promotion of eating behavior |
US5716643A (en) | 1995-06-07 | 1998-02-10 | Hemosphere Inc. | Large scale production of medicine coated crosslinked protein microspheres |
US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
NL1000628C2 (nl) * | 1995-06-22 | 1996-12-24 | Nederland Ptt | Grondstationsysteem omvattende een eerste en een tweede grondstation, alsmede grondstation, alsmede inrichting, alsmede werkwijze. |
US5846933A (en) | 1996-06-28 | 1998-12-08 | Korngold; Robert | CD-4 derived peptides that inhibit immune responses |
US5863529A (en) | 1995-09-20 | 1999-01-26 | Mayo Foundation For Medical Education And Research | Suppression of demyelination by interleukin-6 |
AUPN634595A0 (en) | 1995-11-03 | 1995-11-30 | Borody, Thomas Julius | Improved method for colonic evacuation |
US7081238B2 (en) * | 1995-11-03 | 2006-07-25 | The President And Fellows Of Harvard College | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level |
US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
US5753218A (en) | 1996-05-03 | 1998-05-19 | Schering Corporation | Method for treating inflammation |
WO1997046882A1 (en) * | 1996-06-07 | 1997-12-11 | Immunivest Corporation | Magnetic separation employing external and internal gradients |
US6013633A (en) | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
US5861398A (en) | 1996-08-26 | 1999-01-19 | Alanex Corporation | Benzoperimidine-carboxylic acids and derivatives thereof |
US5776524A (en) * | 1996-10-30 | 1998-07-07 | The Iams Company | Process for treating small intestine bacterial overgrowth in animals |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
US5830668A (en) | 1996-12-13 | 1998-11-03 | Immunosciences Lab, Inc. | Detection of chronic fatigue syndrome |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US5968741A (en) | 1997-04-11 | 1999-10-19 | Cedars-Sinai Medical Center | Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis |
US5911992A (en) | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
US5916869A (en) | 1997-06-13 | 1999-06-29 | North Carolina State University | Method of treating birds in ovo |
US6737408B1 (en) | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
FR2769915B1 (fr) | 1997-10-21 | 2000-10-13 | Synthelabo | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique |
US6255467B1 (en) * | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
US6040188A (en) | 1997-11-18 | 2000-03-21 | The Regents Of The University Of California | In vitro gastrointestinal mimetic protocol for measuring bioavailable contaminants |
US6165997A (en) * | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
AR014069A1 (es) | 1998-01-29 | 2001-01-31 | Kinerton Ltd | Procedimiento para preparar microparticula o microparticulas unidas encapsuladas |
US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
US5968748A (en) | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
US6017879A (en) | 1998-04-03 | 2000-01-25 | B.M.R.A. Corporation B.V. | Template associated NPY Y2-receptor agonists |
US6013622A (en) | 1998-04-15 | 2000-01-11 | Nutriceutical Technology Corporation | Method of regulating appetite and metabolism |
US6264913B1 (en) * | 1998-05-08 | 2001-07-24 | Metabolic Solutions, Inc. | Non-invasive test for assessing bacterial overgrowth of the small intestine |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
US7745216B2 (en) | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
US6851053B1 (en) * | 1999-03-02 | 2005-02-01 | Microsoft Corporation | Multiparty conference authentication |
JP2000282876A (ja) * | 1999-03-31 | 2000-10-10 | Honda Motor Co Ltd | 2サイクルエンジンの排気制御弁装置 |
US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
CA2370590A1 (en) | 1999-04-23 | 2000-11-02 | Meiji Seika Kaisha, Ltd. | Agent for suppressing the odors of sulfides formed through fermentation in the large intestine |
US20030124566A1 (en) * | 2000-02-17 | 2003-07-03 | Kong Ning Steven | 5-Hydroxytryptamine transporter gene polymorphisms |
US6824988B2 (en) * | 2000-05-15 | 2004-11-30 | R.E.D. Laboratories, N.V. | Method and compositions for use in diagnosing and characterizing chronic immune disease |
AU2001261777A1 (en) * | 2000-05-19 | 2001-12-03 | Ancile Pharmaceuticals, Inc. | Treatment for irritable bowel syndrome and related conditions |
US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
AU2007201246B2 (en) | 2001-04-17 | 2008-12-04 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
CA2453837C (en) * | 2001-07-20 | 2011-10-04 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds |
KR20040058324A (ko) | 2001-11-26 | 2004-07-03 | 다이이찌 산토리 파마 가부시키가이샤 | 경비흡수용 의약 조성물 |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
AT501448B1 (de) | 2005-03-02 | 2006-11-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von wässrigen ortho-phthalaldehyd-lösungen |
EP1698630B1 (de) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
1999
- 1999-08-11 US US09/374,142 patent/US6861053B1/en not_active Expired - Lifetime
-
2000
- 2000-08-11 EP EP00952739A patent/EP1200828B1/de not_active Expired - Lifetime
- 2000-08-11 ES ES00952739T patent/ES2295045T3/es not_active Expired - Lifetime
- 2000-08-11 PT PT101771533T patent/PT2256498E/pt unknown
- 2000-08-11 ES ES10177153.3T patent/ES2541471T3/es not_active Expired - Lifetime
- 2000-08-11 EP EP10183213.7A patent/EP2261664B1/de not_active Expired - Lifetime
- 2000-08-11 EP EP10183223.6A patent/EP2261665B1/de not_active Expired - Lifetime
- 2000-08-11 DK DK10177153.3T patent/DK2256498T3/en active
- 2000-08-11 EP EP10177153.3A patent/EP2256498B1/de not_active Expired - Lifetime
- 2000-08-11 ES ES07075358T patent/ES2366235T3/es not_active Expired - Lifetime
- 2000-08-11 AT AT07075358T patent/ATE514946T1/de active
- 2000-08-11 DK DK07075358.7T patent/DK1811303T3/da active
- 2000-08-11 EP EP07075358A patent/EP1811303B1/de not_active Expired - Lifetime
- 2000-08-11 PT PT07075358T patent/PT1811303E/pt unknown
- 2000-08-11 AU AU65383/00A patent/AU6538300A/en not_active Abandoned
- 2000-08-11 AT AT00952739T patent/ATE376673T1/de not_active IP Right Cessation
- 2000-08-11 WO PCT/US2000/022030 patent/WO2001011077A2/en active IP Right Grant
- 2000-08-11 DE DE60036871T patent/DE60036871T2/de not_active Expired - Lifetime
-
2002
- 2002-03-26 US US10/107,240 patent/US6805852B2/en not_active Expired - Lifetime
-
2004
- 2004-08-10 US US10/915,193 patent/US7056686B2/en not_active Expired - Lifetime
-
2005
- 2005-09-23 US US11/234,516 patent/US7452857B2/en not_active Expired - Lifetime
-
2007
- 2007-08-14 US US11/838,672 patent/US7605240B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,631 patent/US7585838B2/en not_active Expired - Fee Related
-
2008
- 2008-09-19 US US12/234,502 patent/US7718608B2/en not_active Expired - Fee Related
-
2009
- 2009-08-28 US US12/550,303 patent/US7935799B2/en not_active Expired - Fee Related
-
2011
- 2011-03-28 US US13/073,169 patent/US8197805B2/en not_active Expired - Lifetime
- 2011-09-28 CY CY20111100937T patent/CY1114368T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE376673T1 (de) | Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten | |
Attiullah et al. | Clinical features of obsessive-compulsive disorder | |
Jones et al. | The cognitive mediation of obsessive-compulsive handwashing | |
Beier et al. | Improved physical fitness correlates with improved cognition in multiple sclerosis | |
Gaudreau et al. | Verbal irony comprehension in older adults with amnestic mild cognitive impairment. | |
Silva et al. | The association between maltreatment in childhood and criminal convictions to age 24: a prospective study of a community sample of males from disadvantaged neighbourhoods | |
Cox et al. | Reading proficiency affects the construct validity of the Stroop test interference score | |
ATE415632T1 (de) | Verfahren zur diagnose und behandlung von morbus crohn | |
Pinsonneault et al. | Low intelligence and poor executive function as vulnerabilities to externalizing behavior | |
Latorre Román et al. | Complex gait is related to cognitive functioning in older people: A cross-sectional study providing an innovative test | |
Wakefield et al. | The importance and limits of harm in identifying mental disorder | |
Zhou et al. | The value of the clock drawing test and the mini‐mental state examination for identifying vascular cognitive impairment no dementia | |
Nieuwenhuis et al. | Increased prevalence of intellectual disabilities in higher-intensity mental healthcare settings | |
ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
Lincoln | Discrepancies between capabilities and performance of activities of daily living in multiple sclerosis patients | |
Elkhamisi et al. | Aggression dimensions in students with autism | |
Fischer et al. | Recency-primacy recognition in Parkinson's disease | |
Koivisto | Population-based dementia screening program in the city of Kuopio, Eastern Finland: evaluation of screening methods, prevalence of dementia and dementia subtypes. | |
Smeraldi et al. | Testing three theories of cognitive dysfunction in alcohol abuse | |
Brand et al. | Qualitative and quantitative differences in cognitive estimation of patients with probable Alzheimer's disease from healthy controls–what are the differences? | |
Gittelman | Indications for the use of stimulant treatment in learning disorders | |
Crocker et al. | Inpatient Consultations of Patients with Functional GI Disorders (FGIDs) at a Tertiary Care Center: The Value of Diagnostic Testing: 1313 | |
Sarah | A visual based cognitive assessment tool (VCAT) for diagnosis of dementia in a multilingual Asian population/Sarah Iyang Kiyu | |
Marzillier | Why Psychologists need to know about Lyme disease | |
Faiz | Lothian assessment for screening cognition in aphasia (LASCA): A new non verbal assessment of cognition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |